158 related articles for article (PubMed ID: 7283558)
1. Postabsorptive urinary hydroxyproline test in patients with metastatic bone disease from breast cancer.
Niell HB; Palmieri GM; Neely CL; McDonald MW
Arch Intern Med; 1981 Oct; 141(11):1471-3. PubMed ID: 7283558
[TBL] [Abstract][Full Text] [Related]
2. The postabsorptive hydroxyproline in the long-term evaluation of patients with breast cancer.
Niell HB; Neely CL; Palmieri GM; McDonald MW
Cancer; 1983 Oct; 52(8):1442-7. PubMed ID: 6616407
[TBL] [Abstract][Full Text] [Related]
3. Total, dialyzable, and nondialyzable postabsorptive hydroxyproline. Values in patients with cancer.
Niell HB; Palmieri GM; Neely CL; Maxwell TA; Hopkins SC; Soloway MS
Arch Intern Med; 1983 Oct; 143(10):1925-7. PubMed ID: 6625779
[TBL] [Abstract][Full Text] [Related]
4. [Hydroxyproline in the diagnosis of bone metastases in breast cancer].
Gasser AB; Depierre D; Alberto P; Courvoisier B
Schweiz Med Wochenschr; 1977 Jul; 107(28):984-6. PubMed ID: 897640
[TBL] [Abstract][Full Text] [Related]
5. Symptomatic relief for patients with osseous metastasis treated with radiation and methylprednisolone: a prospective randomized study.
Teshima T; Inoue T; Inoue T; Ikeda H; Murayama S; Yamazaki H; Ohtani M; Kishi K; Miyata Y
Radiat Med; 1996; 14(4):185-8. PubMed ID: 8916260
[TBL] [Abstract][Full Text] [Related]
6. The postabsorptive urinary hydroxyproline (spot-HYPRO) in patients with multiple myeloma.
Niell HB; Neely CL; Palmieri GM
Cancer; 1981 Aug; 48(3):783-7. PubMed ID: 7248905
[TBL] [Abstract][Full Text] [Related]
7. Value of urinary hydroxyproline and bone isoenzyme of alkaline phosphatase in the early detection and follow-up of bone metastasis in breast cancer patients.
Frenay M; Namer M; Boublil JL; Khater R; Viot M; François E; Milano G
Bull Cancer; 1988; 75(6):533-9. PubMed ID: 3416085
[TBL] [Abstract][Full Text] [Related]
8. [Hydroxyprolinuria in relation to bone metastases in patients with breast cancer].
Rico Lenza H; Millán Núñez-Cortés J; Rodríguez Mora VI; Espinós Pérez D
Rev Esp Oncol; 1980; 27(1):61-6. PubMed ID: 7209108
[TBL] [Abstract][Full Text] [Related]
9. [Use of urinary hydroxyproline excretion as a marker of bone metastases in prostatic cancer (1)].
Kurokawa K; Imai K; Yamanaka H; Tomaru Y; Kitaura K
Hinyokika Kiyo; 1985 Dec; 31(12):2119-25. PubMed ID: 2421558
[TBL] [Abstract][Full Text] [Related]
10. Hydroxyproline and zinc excretion in patients with neoplastic breast disease.
Percudani M; Dell'Anna B; De Lorenzis GF; Ferraccioli GF; Vaona GL
Int Surg; 1981; 66(3):233-6. PubMed ID: 7319736
[TBL] [Abstract][Full Text] [Related]
11. Biochemical picture of bone metabolism in breast cancer patients with bone metastases.
Berruti A; Torta M; Piovesan A; Raucci CA; Orlandi F; Panero A; Dogliotti L; Angeli A
Anticancer Res; 1995; 15(6B):2871-5. PubMed ID: 8669881
[TBL] [Abstract][Full Text] [Related]
12. [Urinary hydroxyproline excretion before and after hypophysectomy in patients with bone metastases from breast cancer].
Ditzel J; Jordal R; Riskoer N
Ugeskr Laeger; 1968 Oct; 130(42):1766-71. PubMed ID: 5724711
[No Abstract] [Full Text] [Related]
13. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K
Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740
[TBL] [Abstract][Full Text] [Related]
14. [Urinary hydroxyproline and cancer of the breast].
Bellido V; Carda P; Mascías E
Rev Esp Oncol; 1983; 30(1):7-16. PubMed ID: 6679910
[No Abstract] [Full Text] [Related]
15. Urinary hydroxyproline excretion in patients with breast cancer.
Cuschieri A; Felgate R
Br J Surg; 1971 Nov; 58(11):862. PubMed ID: 5124876
[No Abstract] [Full Text] [Related]
16. The course of the urinary DPD-crosslink secretion in metastatic breast cancer--a possibility for response assessment.
Lüftner D; Günther S; Flath B; Müller C; Echteroff K; Mergenthaler HG; Wernecke KD; Possinger K
Anticancer Res; 1999; 19(4A):2537-44. PubMed ID: 10470191
[TBL] [Abstract][Full Text] [Related]
17. Alpha CTX as a biomarker of skeletal invasion of breast cancer: immunolocalization and the load dependency of urinary excretion.
Leeming DJ; Delling G; Koizumi M; Henriksen K; Karsdal MA; Li B; Qvist P; Tankó LB; Byrjalsen I
Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1392-5. PubMed ID: 16835341
[TBL] [Abstract][Full Text] [Related]
18. 'Early' breast cancer, bone scanning, and the urinary excretion of hydroxyproline.
Sumner DS; Baum M; Parsons V; Edwards MH
Br J Surg; 1973 Apr; 60(4):306. PubMed ID: 4700234
[No Abstract] [Full Text] [Related]
19. [Urinary hydroxyproline in advanced breast carcinoma and response to treatment with medroxyprogesterone acetate (MAP) in high doses].
Martoni A; Pedelini G; Colalongo G; Biagi R; Mambelli M; Jafelice G; Rocchetta G; Piana E; Pannuti F
Minerva Med; 1980 Sep; 71(31):2215-9. PubMed ID: 7422143
[TBL] [Abstract][Full Text] [Related]
20. [Variable behavior of urinary hydroxyproline in breast cancer with osseous metastases].
Polico C; Nascimben O; Maccari F; Fazzin G
Quad Sclavo Diagn; 1978 Dec; 14(4):486-93. PubMed ID: 757622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
